Numab Therapeutics AG is thrilled to announce its recent successful funding round, raising $50 million to propel its innovative research and development efforts. Renowned for utilizing bioinformatics and artificial intelligence, Arctic Therapeutics (AT) is committed to revolutionizing the drug development landscape. The funding will significantly advance AT’s mission to mitigate the risks associated with traditional drug development, ultimately bringing effective treatments to millions of patients faster and more efficiently than ever before. AT seeks to harness over 20 years of international genomics research to promote a novel, data-driven approach in drug discovery and development.
One of the key areas of focus for AT is its promising drug candidate, AT-001, aimed at combating Alzheimer’s disease. This groundbreaking treatment not only targets the symptoms of dementia but also holds the potential to prevent the disease from progressing, marking a milestone in Alzheimer’s care. The research is underpinned by a close partnership with The Center for Applied Genomics (CAG) at the Children’s Hospital of Philadelphia, emphasizing AT’s dedication to repurposing existing therapies and developing new ones. Founded by Dr. Hakon Hakonarson, a distinguished expert in applied genomics and the visionary behind the world’s largest pediatric biobank and genomic database, AT is poised to make a lasting impact in the field of medicine. This latest funding round serves as a testament to the strategic direction of Arctic Therapeutics and affirms investors’ confidence in its transformative potential in drug development and patient care.
